Telangiectatic Osteosarcoma — a high-grade variant of osteosarcoma characterized by blood-filled cavities lined by malignant cells producing osteoid, first systematically described as a distinct clinicopathologic entity by Huvos and colleagues at Memorial Sloan Kettering in 1982 on the basis of its characteristic macroscopic appearance mimicking aneurysmal bone cyst and its unique microscopic architecture of large blood-filled spaces septated by malignant spindle cells producing delicate osteoid — accounting for approximately 3–12% of all osteosarcomas and representing the variant with the greatest diagnostic challenge due to its macroscopic and radiographic resemblance to aneurysmal bone cyst, with a peak incidence in the second decade of life (median age 15–20 years), a slight male predominance, and a predominant location in the metaphyses of long bones (the distal femur and proximal tibia being most common, mirroring the distribution of conventional osteosarcoma) — presents clinically as a painful, often rapidly enlarging mass with pathological fracture at presentation in approximately 15–30% of cases (a higher rate than conventional osteosarcoma, reflecting the thin cortical shell and blood-filled cavities); radiographically, telangiectatic osteosarcoma is characterized by a predominantly lytic, expansile, permeative lesion without the dense mineralization typical of conventional osteosarcoma, cortical destruction and breakthrough in most cases at diagnosis, periosteal reaction (Codman triangle, sun-burst pattern), and an absent or minimal matrix mineralization pattern that produces an almost purely lytic appearance mimicking aggressive aneurysmal bone cyst or giant cell tumor of bone on plain radiographs; on CT, cortical breakthrough and soft tissue extension are characteristically present, with internal matrix mineralization absent in the majority, and on MRI, telangiectatic osteosarcoma shows fluid-fluid levels within blood-filled cavities (identical to the fluid-fluid levels of aneurysmal bone cyst on MRI), heterogeneous signal due to hemorrhage at different stages, and surrounding soft tissue mass with internal septal enhancing nodules that help distinguish it from aneurysmal bone cyst (which lacks solid enhancing nodularity and true sarcomatous cells on septae). Pathologically, telangiectatic osteosarcoma displays its characteristic architecture of large dilated blood-filled spaces (cystic cavities filled with blood and necrotic debris) separated by thin septa lined by markedly atypical malignant cells producing delicate lace-like osteoid — a pattern that can be misinterpreted as aneurysmal bone cyst (which contains benign spindle cells without cytologic atypia lining blood-filled spaces) or giant cell tumor of bone (which contains osteoclast-type giant cells and uniform mononuclear stromal cells without osteoid production) if the malignant cytologic features of the lining cells and the presence of osteoid are not recognized; the diagnosis requires recognition of high-grade cytologic atypia, atypical mitoses, necrosis, and osteoid production in the septal lining cells, and adequate sampling is critical because undersampled biopsies may show only the blood-filled cavities without capturing the diagnostic malignant septal component; molecular profiling of telangiectatic osteosarcoma shares the complex chromosomal instability and copy number alterations of conventional osteosarcoma without a recurrent single defining molecular alteration. Contemporary telangiectatic osteosarcoma management mirrors conventional high-grade osteosarcoma management — MAP protocol neoadjuvant chemotherapy (cisplatin, doxorubicin, high-dose methotrexate with leucovorin rescue) followed by wide surgical resection with limb salvage in anatomically feasible cases (endoprosthetic reconstruction for metaphyseal disease) and adjuvant chemotherapy, with 5-year overall survival of 57–77% in recent series at high-volume bone sarcoma programs, outcomes that are comparable to or slightly inferior to conventional osteosarcoma when telangiectatic osteosarcoma is appropriately diagnosed and treated with MAP protocol chemotherapy.
Telangiectatic osteosarcoma technology platforms — whether supporting bone sarcoma programs coordinating MAP protocol neoadjuvant chemotherapy (cisplatin, doxorubicin, high-dose methotrexate with leucovorin rescue requiring serum methotrexate level monitoring and time-critical leucovorin rescue scheduling), diagnostic imaging and pathology laboratories distinguishing telangiectatic osteosarcoma from aneurysmal bone cyst and giant cell tumor of bone (the diagnostic pitfall where misclassification leads to curettage instead of wide resection), surgical platforms managing limb salvage wide resection and endoprosthetic reconstruction, and long-term surveillance platforms managing serial imaging for local recurrence and pulmonary metastasis — must maintain the availability and performance standards that telangiectatic osteosarcoma's chemotherapy complexity, diagnostic challenge, surgical precision, and metastatic risk require. This guide explains why telangiectatic osteosarcoma tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the multimodal oncologic management of this high-grade osteosarcoma variant with its characteristic diagnostic and pathological fracture challenges.
Why Telangiectatic Osteosarcoma Tech Platforms Require Specialized Monitoring Attention
Telangiectatic osteosarcoma management is defined by the diagnostic challenge of distinguishing the blood-filled cavities of telangiectatic osteosarcoma from aneurysmal bone cyst and giant cell tumor of bone — where misclassification at biopsy leads to curettage (appropriate for benign ABC but resulting in tumor dissemination and local recurrence in telangiectatic osteosarcoma), the pathological fracture risk at presentation requiring orthopedic stabilization concurrent with chemotherapy initiation, the MAP protocol neoadjuvant chemotherapy complexity requiring serum methotrexate monitoring and time-critical leucovorin rescue, and the surgical requirements for limb salvage wide resection and endoprosthetic reconstruction in an adolescent population. Technology failures in these domains create disruptions calibrated to the diagnostic accuracy, fracture management, chemotherapy safety, and surgical precision consequences of a high-grade osteosarcoma variant where the most common diagnostic error — misclassification as benign aneurysmal bone cyst — leads directly to tumor dissemination and loss of surgical control.
Pathology platforms must prevent misclassification as aneurysmal bone cyst. Histomorphologic characterization of malignant septal lining cells with high-grade cytologic atypia and osteoid production (confirming telangiectatic osteosarcoma over aneurysmal bone cyst), adequate biopsy sampling protocols, and intraoperative frozen section guidance require reliable pathology platform availability during business hours and during operative sessions. Monitor pathology platforms at 1-minute intervals during business hours and during operative sessions.
Medical oncology platforms manage time-critical MAP protocol neoadjuvant chemotherapy. High-dose methotrexate with leucovorin rescue, cisplatin, and doxorubicin — the MAP protocol standard requiring serum methotrexate level monitoring at 24, 48, and 72 hours post-infusion and time-critical leucovorin rescue dose escalation — require platform availability throughout the infusion period and at the precise moments of serum methotrexate level review. Monitor oncology platforms at 1-minute intervals during infusion.
Orthopedic and fracture management platforms coordinate pathological fracture stabilization. Pathological fracture at presentation (occurring in 15–30% of telangiectatic osteosarcoma cases at the time of diagnosis) requires urgent orthopedic stabilization planning concurrent with chemotherapy initiation and surgical oncology staging, with stabilization approach (intramedullary nailing versus external fixation) directly affecting the subsequent limb salvage surgical strategy. Monitor orthopedic platforms at 1-minute intervals during clinical encounters when fracture management is being coordinated.
Surgical platforms coordinate wide resection and endoprosthetic reconstruction. Preoperative MRI characterizing the soft tissue extent beyond the blood-filled cavities, CT defining cortical destruction extent and pathological fracture gap, surgical templating for endoprosthetic sizing, and limb salvage reconstructive surgery documentation require platform availability throughout the operative period. Monitor surgical platforms at 1-minute intervals during operative sessions.
What to Monitor on a Telangiectatic Osteosarcoma Tech Platform
Diagnostic Imaging and Pathology — Distinguishing from Aneurysmal Bone Cyst
Monitor plain radiograph records documenting the predominantly lytic, expansile lesion with cortical destruction and Codman triangle or sun-burst periosteal reaction (the purely lytic appearance that triggers the critical differential diagnosis with aneurysmal bone cyst), CT records characterizing cortical breakthrough and soft tissue extension and documenting the absence of dense matrix mineralization, MRI records documenting fluid-fluid levels within blood-filled cavities (identical to ABC on MRI) alongside solid enhancing nodularity on the septal surfaces (the MRI feature most predictive of telangiectatic osteosarcoma over ABC), biopsy histomorphologic characterization records (high-grade cytologic atypia of septal lining cells, malignant mitoses, necrosis, and delicate osteoid production in the septa confirming telangiectatic osteosarcoma; versus bland spindle cells without atypia and without osteoid production in ABC), intraoperative frozen section records confirming the diagnosis before definitive surgical approach, and tumor board radiology-pathology correlation records at 1-minute intervals during clinical hours. Alert immediately — imaging and pathology platform failures during the critical diagnosis determination of telangiectatic osteosarcoma versus aneurysmal bone cyst eliminate the diagnostic team's access to MRI septal nodularity characterization and comparative histomorphology at the exact moment when the wrong diagnosis directs a patient toward curettage, which results in local tumor dissemination and loss of the limb salvage window.
Medical Oncology and MAP Protocol Chemotherapy
Monitor high-dose methotrexate prescribing and pharmacy preparation records (dose per protocol, infusion rate, hydration documentation), serum methotrexate level records at 24, 48, and 72 hours post-infusion (the time-critical monitoring that determines leucovorin rescue adequacy), leucovorin rescue dose and schedule records (standard versus escalated rescue based on methotrexate clearance curve), creatinine clearance documentation before each cisplatin cycle, doxorubicin administration records and cumulative dose tracking with echocardiographic ejection fraction monitoring, cisplatin ototoxicity monitoring records (audiogram scheduling and documentation), complete blood count and dose modification documentation, MAP protocol cycle scheduling and response assessment imaging records, neoadjuvant versus adjuvant cycle documentation, and pathological fracture concurrent stabilization and chemotherapy coordination records at 1-minute intervals during infusion sessions. Alert immediately — MAP protocol platform failures during high-dose methotrexate infusion with active leucovorin rescue scheduling disrupt the serum methotrexate level review workflow at the 48-hour time point, where delayed documentation of an elevated methotrexate level delays escalated leucovorin rescue initiation and creates risk of severe and potentially fatal methotrexate toxicity in an adolescent with telangiectatic osteosarcoma undergoing neoadjuvant chemotherapy.
Pathological Fracture Management and Orthopedic Stabilization
Monitor urgent orthopedic consultation and fracture assessment records for telangiectatic osteosarcoma presenting with pathological fracture, stabilization approach planning records (intramedullary nail versus external fixation versus cast immobilization, with documentation of the approach's impact on subsequent wide resection margins and limb salvage planning), concurrent chemotherapy initiation and fracture stabilization coordination records, fracture healing and cortical reconstitution monitoring during neoadjuvant chemotherapy records, revised surgical resection planning records accounting for fracture gap and callus extent, and rehabilitation and weight-bearing protocol records during chemotherapy at 1-minute intervals during clinical encounter hours when fracture management is being actively coordinated. Alert immediately — orthopedic platform failures during pathological fracture stabilization planning for a newly diagnosed telangiectatic osteosarcoma disrupt the coordination between orthopedic stabilization approach selection and limb salvage surgical planning, where the wrong stabilization approach (e.g., intramedullary nail contaminating the medullary canal) eliminates the limb salvage option that would otherwise be available after neoadjuvant chemotherapy.
Surgical Planning and Limb Salvage Resection
Monitor preoperative MRI records characterizing the soft tissue extension of telangiectatic osteosarcoma beyond the blood-filled cavities (the critical MRI finding that establishes the true extraosseous extent of disease that must be included within wide resection margins), CT records defining the cortical destruction extent and pathological fracture gap (determining the bone resection length), surgical templating records for endoprosthetic sizing (modular rotating hinge or distal femoral replacement for distal femoral lesions; proximal tibial replacement for proximal tibial lesions), neoadjuvant response assessment imaging records (CT and MRI comparing pre- and post-chemotherapy soft tissue extent and cortical involvement), intraoperative frozen section margin records, and endoprosthetic reconstruction operative documentation records at 1-minute intervals during operative sessions. Alert immediately — surgical planning platform failures during limb salvage wide resection for telangiectatic osteosarcoma eliminate access to preoperative MRI characterizing the true soft tissue extent of the blood-filled tumor and the templating records confirming endoprosthetic sizing, creating direct risk of inadequate surgical margins or mismatched prosthetic implant sizing.
Post-treatment Surveillance and Metastasis Detection
Monitor serial MRI local site surveillance scheduling (every 3 months for years 1–2, every 6 months for years 3–5 post-resection), CT chest surveillance scheduling for pulmonary metastasis detection (the dominant site of systemic relapse in osteosarcoma), plain radiograph surveillance for endoprosthetic integrity and implant loosening, imaging result integration and comparison with prior studies, tumor board documentation for suspicious local or pulmonary findings, CT-guided biopsy or resection scheduling for suspected recurrence, and pulmonary metastasectomy referral records during business hours. Alert on sustained failures — surveillance platform outages delay detection of pulmonary metastasis in a patient whose oligometastatic pulmonary relapse may remain amenable to bilateral thoracoscopic or open metastasectomy with curative intent.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Telangiectatic osteosarcoma programs coordinate across orthopedic oncology, medical oncology, clinical pharmacy, musculoskeletal pathology, musculoskeletal radiology, reconstructive orthopedic surgery, and thoracic surgery for metastasectomy — authentication failures simultaneously block every team member whose platform access is required to execute MAP chemotherapy, diagnostic confirmation, pathological fracture management, surgical planning, and surveillance imaging.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, chemotherapy management systems, surgical planning platforms, pathology reporting systems, and surveillance imaging platforms. Certificate errors disrupt the chemotherapy coordination, diagnostic review, fracture management, and surveillance workflows of telangiectatic osteosarcoma management.
HIPAA and Oncology Data Privacy Considerations
Telangiectatic osteosarcoma technology platforms handle sensitive PHI including MAP protocol chemotherapy administration records with high-dose methotrexate levels and leucovorin rescue scheduling, biopsy pathology reports documenting the critical distinction between telangiectatic osteosarcoma and aneurysmal bone cyst, pathological fracture emergency orthopedic stabilization records, limb salvage wide resection and endoprosthetic reconstruction operative records, and post-treatment surveillance imaging for a predominantly adolescent patient population. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing chemotherapy administration timing records and serum methotrexate level monitoring — where platform availability at the moment of 48-hour serum methotrexate level review determines whether escalated leucovorin rescue is initiated on schedule — and for platforms managing the diagnostic pathology records where the telangiectatic osteosarcoma versus aneurysmal bone cyst distinction determines the entire treatment trajectory, both privacy and availability standards must reflect the sensitivity of adolescent oncology records and the operational criticality of real-time clinical decision support. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for bone sarcoma programs managing telangiectatic osteosarcoma's intersection of chemotherapy safety, diagnostic accuracy, pathological fracture management, surgical oncology, and surveillance PHI.
Alerting Strategy for Telangiectatic Osteosarcoma Tech Platforms
Immediate alerting during chemotherapy infusion: MAP protocol platforms, high-dose methotrexate and leucovorin rescue scheduling, serum methotrexate level monitoring, cisplatin and doxorubicin administration, echocardiographic and audiometric monitoring. These cannot fail during active MAP infusion without creating direct patient safety risk.
Immediate alerting during operative sessions: Surgical planning platforms, intraoperative frozen section, endoprosthetic templating records, intraoperative fluoroscopy, and operative documentation. These cannot fail during wide resection and limb salvage reconstruction without direct surgical consequence.
Immediate business-hours alert: Diagnostic pathology (telangiectatic osteosarcoma vs. ABC distinction), imaging interpretation, fracture stabilization planning, implant ordering, and tumor board review platforms. Alert the moment these fail during active clinical or diagnostic encounters.
Sustained-failure alert (10–15 minutes): Post-treatment local MRI surveillance, CT chest scheduling, and endoprosthetic implant integrity monitoring platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms telangiectatic osteosarcoma platform availability from the geographies where high-volume bone sarcoma programs with MAP protocol expertise, telangiectatic osteosarcoma diagnostic experience, pathological fracture management capability, and limb salvage endoprosthetic reconstruction concentrate.
Status Page for Telangiectatic Osteosarcoma Care Team Communication
A real-time status page gives medical oncologists managing MAP neoadjuvant chemotherapy, clinical pharmacists monitoring serum methotrexate levels and leucovorin rescue timing, musculoskeletal pathologists confirming the telangiectatic osteosarcoma versus aneurysmal bone cyst diagnosis on biopsy, musculoskeletal radiologists characterizing septal nodularity on MRI, orthopedic oncologists planning pathological fracture stabilization and limb salvage resection, and surveillance coordinators scheduling serial MRI and CT chest immediate platform visibility without requiring inbound IT support contact. During a chemotherapy platform outage when a clinical pharmacist must confirm leucovorin rescue dosing for an adolescent with telangiectatic osteosarcoma of the distal femur 48 hours post-methotrexate infusion while the serum methotrexate level is pending, a status page enables immediate activation of emergency leucovorin rescue protocols without waiting for IT status communication.
Include the status page URL in MAP chemotherapy emergency downtime procedures, diagnostic radiology and pathology contingency procedures for the telangiectatic osteosarcoma/ABC distinction workup, fracture stabilization emergency protocols, surgical planning contingency procedures, and surveillance imaging fallback workflows.
Vigilmon Setup for Telangiectatic Osteosarcoma Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | MAP protocol / methotrexate + leucovorin rescue (infusion hours) | 1 min | Slack + PagerDuty (infusion hours) | | Serum methotrexate level monitoring (24/48/72 hr) | 1 min | Slack + PagerDuty (infusion hours) | | Cisplatin / doxorubicin / echocardiography / audiometry | 1 min | Slack + PagerDuty (clinical hours) | | Diagnostic pathology / telangiectatic vs. ABC distinction | 1 min | Slack + PagerDuty (business hours) | | MRI / CT imaging (septal nodularity and cortical destruction) | 1 min | Slack + PagerDuty (clinical hours) | | Pathological fracture / orthopedic stabilization planning | 1 min | Slack + PagerDuty (clinical hours) | | Surgical planning / endoprosthetic templating (operative hours) | 1 min | Slack + PagerDuty (surgical hours) | | Intraoperative frozen section / fluoroscopy | 1 min | Slack + PagerDuty (surgical hours) | | Neoadjuvant response imaging / tumor board review | 2 min | Slack (business hours) | | MRI local surveillance / CT chest scheduling | 2 min | Slack (business hours) | | Endoprosthetic implant integrity / plain radiograph surveillance | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure MAP protocol platforms with immediate alerting during infusion windows — including methotrexate, serum level monitoring, leucovorin rescue scheduling, cisplatin, and doxorubicin administration
- Add diagnostic pathology platforms for the telangiectatic osteosarcoma versus aneurysmal bone cyst distinction with immediate business-hours alerting
- Configure MRI and CT imaging platforms with immediate clinical-hours alerting (the septal nodularity characterization that distinguishes telangiectatic osteosarcoma from ABC is MRI-dependent)
- Add pathological fracture and orthopedic stabilization planning platforms with immediate clinical-hours alerting
- Configure surgical planning and endoprosthetic templating platforms with immediate alerting during operative windows
- Add intraoperative frozen section and fluoroscopy platforms with immediate surgical-hours alerting
- Configure neoadjuvant response imaging and tumor board review with sustained-failure alerting
- Add local MRI surveillance and CT chest scheduling with sustained-failure alerting
- Configure endoprosthetic implant integrity plain radiograph surveillance with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, chemotherapy, pathology, imaging, surgical, and surveillance domains
- Add the status page URL to MAP chemotherapy emergency downtime procedures, telangiectatic osteosarcoma/ABC diagnostic contingency protocols, fracture stabilization emergency procedures, and surveillance fallback workflows
Conclusion
Telangiectatic osteosarcoma technology platforms are embedded in clinical decisions where diagnostic platform availability during the critical determination of telangiectatic osteosarcoma versus aneurysmal bone cyst — where the musculoskeletal pathologist reviewing the needle biopsy of a blood-filled lytic lesion in the distal femur of a 16-year-old must confirm that the spindle cells lining the blood-filled spaces demonstrate high-grade cytologic atypia, atypical mitoses, and delicate osteoid production (confirming telangiectatic osteosarcoma and directing the patient to MAP protocol chemotherapy and limb salvage wide resection) rather than showing bland fibrous cells without atypia and without osteoid (which would confirm aneurysmal bone cyst and direct the patient to curettage with adjuvant local treatment), and where the musculoskeletal radiologist reviewing the MRI must identify and characterize the solid enhancing nodularity at the septal surfaces (the MRI feature most predictive of telangiectatic osteosarcoma over aneurysmal bone cyst) — cannot be disrupted by platform unavailability at the precise moment when the distinction between high-grade osteosarcoma and benign cystic lesion determines whether curettage disseminates the tumor or whether MAP chemotherapy and wide resection begin; where MAP protocol platform availability during high-dose methotrexate infusion — where the clinical pharmacist must review the serum methotrexate level drawn at 48 hours post-infusion to determine whether the methotrexate clearance curve is following the expected trajectory or whether the delayed clearance pattern that predicts severe mucositis, myelosuppression, and nephrotoxicity is emerging, triggering escalated leucovorin rescue before the toxicity becomes clinically irreversible, and where the leucovorin dose escalation and rescue schedule must be updated in the chemotherapy management platform and communicated to the infusion nursing team before the 8-hour leucovorin rescue window closes — cannot be interrupted by a platform outage during the 48-hour post-infusion monitoring window for an adolescent with telangiectatic osteosarcoma who may be developing delayed methotrexate clearance; and where surveillance platform availability at 30 months post-resection — when the oncology surveillance coordinator is attempting to schedule the CT chest for an 18-year-old who completed MAP protocol adjuvant chemotherapy and limb salvage distal femoral endoprosthetic reconstruction at age 16 and whose surveillance imaging is now 3 months overdue because of a scheduling system failure, and where the oncology team is concerned that a pulmonary nodule identified on the 24-month CT chest has grown to the 12mm threshold that warrants urgent tumor board review and CT-guided biopsy to determine whether this represents early pulmonary metastasis amenable to metastasectomy — determines whether this patient's early pulmonary relapse is identified and surgically addressed before bilateral pulmonary metastatic progression forecloses curative salvage options. A pathology platform that fails when the musculoskeletal pathologist is making the critical telangiectatic osteosarcoma versus aneurysmal bone cyst distinction on biopsy, a chemotherapy platform inaccessible when the pharmacist is monitoring 48-hour serum methotrexate clearance and leucovorin rescue scheduling, a surveillance imaging scheduling platform unavailable when an overdue CT chest must be booked to follow a suspicious pulmonary nodule — these are not IT incidents. They are clinical disruptions in the management of a high-grade osteosarcoma variant where diagnostic accuracy prevents curettage-mediated tumor dissemination, chemotherapy platform availability prevents methotrexate toxicity, and timely surveillance detects early pulmonary relapse while metastasectomy remains possible.
Uptime monitoring gives telangiectatic osteosarcoma tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to bone sarcoma surgery programs, medical oncology services, musculoskeletal pathology laboratories, and compliance auditors that platform operational reliability matches the diagnostic precision requirements, chemotherapy safety demands, surgical planning precision, and long-term surveillance obligations of modern telangiectatic osteosarcoma management.
Start monitoring your telangiectatic osteosarcoma care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #telangiectatic #osteosarcoma #bonesarcoma #bloodfilled #aneurysmalbone #MAPprotocol #methotrexate #leucovorin #cisplatin #doxorubicin #pathologicalfracture #limbsalvage #endoprosthesis #musculoskeletaloncology #adolescent #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre